GCG and pancreatic neuroendocrine tumor: These findings indicate that targeting MYCN expression to GFAP-positive cells cause glucagon-producing pancreatic neuroendocrine tumors and pituitary adenomas in transgenic mice and that MYCN expression is detectable in a subset of human PanNETs.